← Human Trials & Peer-Reviewed Studies
Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL): Effects on Bone Structure and Architecture.
Plain-language guide to PMID 29408561 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 50 women.
Key Facts
- PMID
- 29408561
- Journal
- Contemporary clinical trials
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Donlon CM et al. (9 authors)
- DOI
- 10.1016/j.cct.2018.02.003
- Registered trial
- NCT01747447
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
The ancillary study, VITAL: Effects on Bone Structure and Architecture, is testing effects of vitamin D3 and/or omega-3 FAs on musculoskeletal outcomes and body composition in a subcohort of 771 participants.
At in-person visits at the Harvard Catalyst Clinical and Translational Science Center (CTSC), participants completed bone density/architecture, body composition, and physical performance assessments at baseline and two-year follow-up.
Who Took Part
According to the abstract, 50 women were involved.
PubMed indexes the participants as middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
What Was Measured
The ancillary study, VITAL: Effects on Bone Structure and Architecture, is testing effects of vitamin D3 and/or omega-3 FAs on musculoskeletal outcomes and body composition in a subcohort of 771 participants.
At in-person visits at the Harvard Catalyst Clinical and Translational Science Center (CTSC), participants completed bone density/architecture, body composition, and physical performance assessments at baseline and two-year follow-up.
Topics PubMed links to this paper include Absorptiometry, Photon, Biological Availability, Body Composition, Bone Density, Cardiovascular Diseases, Dietary Supplements and Fatty Acids, Omega-3.
Author keywords: Bone mineral density, Omega-3 fatty acids, Physical performance, Sex differences and Vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 50 women.
The publication is from 2018 (Contemporary clinical trials), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.